Almirall stock consolidates after half-year 2026 results and guidance

Published on 09/11/2026 at 21:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall stock closed at EUR 78.20 on September 9, 2026 in Madrid after a 2.25 percent decline, as investors digested the company’s half-year 2026 figures and guidance. The shares trade noticeably below the average analyst target of EUR 102.94, highlighting upside potential but also execution risk.

Pop-Art-Comic einer Dermatologin, die mit Lupe die Haut einer Patientin untersucht — Almirall S.A. (ES0157097017) inspiriert Pop-Art-Comic-Szene einer Dermatologin bei Hautuntersuchung mit Lupe, farbenfroh, Illustration mit AI erstellt.

Almirall stock closed at EUR 78.20 on its Spanish home market on September 9, 2026, down 2.25 percent from the previous session as investors continued to digest the company’s half-year 2026 figures and guidance commentary from earlier in the week. According to Ad-hoc-news, that move left the Barcelona-based dermatology specialist Almirall S.A. (ISIN ES0157097017) lagging broader European health-care benchmarks on the day.

Half-year 2026 figures drive sentiment

Per the company’s half-year 2026 release, Almirall reported revenue growth and reiterated its guidance, which has become a key reference point for investors evaluating the stock around September 9, 2026. According to Almirall, the most recent interim report covers the first half of 2026 and provides updated revenue, earnings and margin data that underpin the current outlook for the remainder of the year. The market reaction since that release shows how closely the share price is tied to the company’s ability to deliver on that guidance.

Investors also pay attention to how the latest half-year numbers compare with the prior-year period, because year-on-year dynamics often drive expectations for future quarters. As Almirall explains in its half-year 2026 documentation, the company uses these interim figures to update its guidance range and to highlight trends in core dermatology franchises, which can either support or pressure the shares depending on whether those trends align with analyst expectations.

Analyst targets underscore valuation gap

Alongside the half-year numbers, the valuation conversation around Almirall stock is increasingly shaped by analyst price targets. The recent wrap at Ad-hoc-news cites MarketScreener data showing that a group of eight analysts carry an average target of EUR 102.94 for the shares. With the stock closing at EUR 78.20 on September 9, 2026, this implies a gap of roughly EUR 24.74 per share between the current market level and the average target, a quantified difference that puts the focus on the execution risks embedded in that upside.

For investors, the key question is whether Almirall’s half-year 2026 revenue and earnings trajectory can justify that EUR 102.94 average target within a reasonable time frame. According to Almirall, the guidance for full-year 2026 is built on continued growth in dermatology, disciplined cost control and selective investment in innovation. Any deviation from these assumptions, for example through slower-than-expected product uptake or margin pressure, would affect how quickly the share price can close the gap to analyst targets.

Stock level and trading metrics

Beyond fundamentals and analyst views, market data provide another lens on Almirall stock. The closing price of EUR 78.20 on September 9, 2026 on the Madrid market marked a 2.25 percent decline from the prior session’s close, with a reported trading volume of 45,743 shares according to the recent summary at Ad-hoc-news. In that context, the share price trades significantly below the cited average target of EUR 102.94, highlighting both perceived upside and the need for continued delivery on financial targets.